PRMT7: a survive-or-die switch in cancer stem cells

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/. The Creative Commons Public Domain Dedication waiver (http:// creat iveco mmons. org/ publi cdoma in/ zero/1. 0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Cancer stem-like cells (CSCs) are involved in initiation, resistance and relapse of cancer [1, 2]. Identifying targets uniquely expressed in CSCs, instead their normal counterparts, has been puzzling the field of cancer biology. In the quintessential paradigm of CSCs in chronic myeloid leukemia (CML), resistance at least partially conferred by leukemia stem cells (LSCs) remains an increasing threat in patients diagnosed with CML [3, 4] despite tyrosine kinase inhibitors such as Imatinib mesylate magically prolonging the survival and improving life quality. In a recent issue of Cell Metabolism, Liu et al. [5] have demonstrated that protein arginine methyltransferase 7 (PRMT7) get hold of a survive-or-die switch in CML LSCs. Indeed, targeting PRMT7 by either genetic or pharmacological approaches selectively eliminate LSCs while sparing normal counterpart cells. The mechanism has been well illustrated. These findings have brought us a phenomenal therapeutic target for CSCs. Epigenetics provide rooms for recognizing the intricate regulation of stemness [6–8]. In their studies, Liu et al. [5] chose PRMT7 based on differential expression in CML LSCs, and authors took advantages of genetic and pharmacological tactics to comprehensively characterize the function of PRMT7 in survival and self-renewal of CML LSCs. First, they generated hematopoietic cell-specific Prmt7 knockout mice to investigate the role of Prmt7 in leukemogenesis of BCR-ABL-driven CML. Interestingly, the authors found that conditional knockout (CKO) of Prmt7 markedly delayed the development of leukemia, and significantly mitigated leukemia burden in CML mice. Of note, Prmt7 CKO dramatically reduced the populations of leukemia stem/progenitor cells (LSPCs) and the frequency of LSCs. Prmt7 CKO also suppressed the CFC/replating capacity of LSCs and the disease reconstitution ability of LSCs in secondary recipients. These lines of compelling evidence indicate that PRMT7 is required for the self-renewal of LSCs. In the meantime, Prmt7 CKO did not impact either the frequency of hematopoietic stem cells (HSCs), or their function of normal HSCs. After obtaining evidence that PRMT7 regulates LSCs in a methyltransferase catalysis-dependent manner, the authors set out to develop small molecule inhibitors against PRMT7. Authors successfully synthesized a small inhibitor, JS1310, which selectivity inhibited PRMT7 but not other PRMT family members. In vivo studies using JS1310 treatment prominently eliminated LSCs and prolonged survival of CML mice. Most importantly, authors also investigated the effects of JS1310 on primary CD34+ cells from CML patients or healthy donors. JS1310 profoundly suppressed the survival and self-renewal ability of CML CD34+ cells without affecting normal CD34+ cells. In a patient-derived xenograft model, JS1310 treatment showed a significant inhibition in the long-term engraftment capacity of human CML CD34+ cells. Overall, PRMT7 may represent a unique and valuable therapeutic target against CML LSCs. To gain insight into the underlying mechanism, the authors did RNA-seq analysis and found that glycine decarboxylase (GLDC) [9, 10], a rate-limiting enzyme in glycine metabolism regulation network, was significantly downregulated in Prmt7-CKO LSCs compared to wildtype counterparts. Rescue experiments revealed that GLDC regulated LSCs in an enzyme activity-dependent manner. Furthermore, ChIP assay showed that the Open Access

Cancer stem-like cells (CSCs) are involved in initiation, resistance and relapse of cancer [1,2]. Identifying targets uniquely expressed in CSCs, instead their normal counterparts, has been puzzling the field of cancer biology. In the quintessential paradigm of CSCs in chronic myeloid leukemia (CML), resistance at least partially conferred by leukemia stem cells (LSCs) remains an increasing threat in patients diagnosed with CML [3,4] despite tyrosine kinase inhibitors such as Imatinib mesylate magically prolonging the survival and improving life quality. In a recent issue of Cell Metabolism, Liu et al. [5] have demonstrated that protein arginine methyltransferase 7 (PRMT7) get hold of a survive-or-die switch in CML LSCs. Indeed, targeting PRMT7 by either genetic or pharmacological approaches selectively eliminate LSCs while sparing normal counterpart cells. The mechanism has been well illustrated. These findings have brought us a phenomenal therapeutic target for CSCs.
Epigenetics provide rooms for recognizing the intricate regulation of stemness [6][7][8]. In their studies, Liu et al. [5] chose PRMT7 based on differential expression in CML LSCs, and authors took advantages of genetic and pharmacological tactics to comprehensively characterize the function of PRMT7 in survival and self-renewal of CML LSCs. First, they generated hematopoietic cell-specific Prmt7 knockout mice to investigate the role of Prmt7 in leukemogenesis of BCR-ABL-driven CML. Interestingly, the authors found that conditional knockout (CKO) of Prmt7 markedly delayed the development of leukemia, and significantly mitigated leukemia burden in CML mice. Of note, Prmt7 CKO dramatically reduced the populations of leukemia stem/progenitor cells (LSPCs) and the frequency of LSCs. Prmt7 CKO also suppressed the CFC/replating capacity of LSCs and the disease reconstitution ability of LSCs in secondary recipients. These lines of compelling evidence indicate that PRMT7 is required for the self-renewal of LSCs. In the meantime, Prmt7 CKO did not impact either the frequency of hematopoietic stem cells (HSCs), or their function of normal HSCs.
After obtaining evidence that PRMT7 regulates LSCs in a methyltransferase catalysis-dependent manner, the authors set out to develop small molecule inhibitors against PRMT7. Authors successfully synthesized a small inhibitor, JS1310, which selectivity inhibited PRMT7 but not other PRMT family members. In vivo studies using JS1310 treatment prominently eliminated LSCs and prolonged survival of CML mice. Most importantly, authors also investigated the effects of JS1310 on primary CD34 + cells from CML patients or healthy donors. JS1310 profoundly suppressed the survival and self-renewal ability of CML CD34 + cells without affecting normal CD34 + cells. In a patient-derived xenograft model, JS1310 treatment showed a significant inhibition in the long-term engraftment capacity of human CML CD34 + cells. Overall, PRMT7 may represent a unique and valuable therapeutic target against CML LSCs.
To gain insight into the underlying mechanism, the authors did RNA-seq analysis and found that glycine decarboxylase (GLDC) [9,10], a rate-limiting enzyme in glycine metabolism regulation network, was significantly downregulated in Prmt7-CKO LSCs compared to wildtype counterparts. Rescue experiments revealed that GLDC regulated LSCs in an enzyme activity-dependent manner. Furthermore, ChIP assay showed that the symmetric methylation of H2AR3 by PRMT7 decreased the enrichment of TRPS1 at the promoter region of GLDC, suggesting that transcriptional repressor GATA binding 1 (TRPS1) may be a mediator for PRMT7 to regulate GLDC. Surprisingly, PRMT7 CKO did not alter TRPS1 and GLDC expression in normal HSCs. This may provide a well and helpful explanation for the phenotype that loss of PRMT7 is not detrimental to normal HSCs.
Gene Ontology analysis revealed that genes related glycine and serine metabolism pathway were significantly enriched in the Prmt7 CKO LSCs. High pressure-liquid chromatography-mass spectrometry analysis indicated a progressive increase in intracellular glycine and serine with progression of CML disease in CML mice. Besides, loss of PRMT7 resulted in excessive accumulation of glycine in LSCs.
Glycine generated from serine by serine hydroxymethyltransferase 2 (SHMT2) can be converted to either non-toxic 5, 10-methylene-tetrahydrofolate (5, 10-MTHF) by GLDC or toxic methylglyoxal by glycine C-acetyltransferase (GCAT) [11,12]. The authors hypothesized that the increased apoptosis in LSCs might be implemented by toxic methylglyoxal which is converted from excess glycine in Prmt7-CKO LSCs. As expected, methylglyoxal level was remarkably increased in Prmt7-CKO LSCs from CML mice or PRMT7 inhibitor-treated CD34 + cells from patients with CML. Methylglyoxal treatment indeed suppressed survival and self-renewal of LSCs. Prmt7-CKO CML mice fed with serine and glycine-free (SG-free) diet exhibited shorted survival than those fed with control diet. SG-free diet also reversed the Prmt7 CKO-mediated decrease in leukemia cells and LSPCs.
Taken together, the authors proposed the working model (Fig. 1). In the context of intact PRMT7 overexpressed in LSCs, glycine metabolism affluently provides 5, 10-MTHF allowing LSCs metabolic addiction. In the context of PRMT7 deletion or inhibition, however, not only the pro-survival of metabolic addiction was blocked but also the glycine metabolism is reshaped to generate excessive methylglyoxal, which is poisonous to LSCs. In the case of normal HSCs absent of PRMT7 overexpression, inhibition of PRMT7 would not kill normal HSCs because of lack of the target. These findings have underscored that PRMT7 is a promisingly selective target of LSCs, and greatly improved our understanding on epigenetic regulation of CSCs. However, relevant question like how PRMT7 is overexpressed in CML LSCs remain to be addressed in future.
Author's contributions CN wrote the commentary. The author(s) read and approved the final manuscript.

Competing interests
The author declares no financial conflict of interest. Christophe Nicot is Editorin-Chief of Molecular Cancer.

Learn more biomedcentral.com/submissions
Ready to submit your research Ready to submit your research ? Choose BMC and benefit from: ? Choose BMC and benefit from: